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Summary The data on 914 patients enrolled in four randomised trials in advanced ovarian cancer, consec-
utively conducted by the same cooperative group between 1978 and 1986, were analysed with the aims of: (1)
determining the impact of selected prognostic variables on survival; (2) finding, from the interaction of
favourable prognostic factors and treatment, an approximate estimate of the magnititude of the survival
advantage associated with the use of platinum-based combination chemotherapy. The overall 3-year survival
in this series of patients is twice that reported historically (22%; 95% CL 18.7--25.4). The proportional hazard
regression model was used to perform the analysis on survival. Residual tumour size, age, FIGO stage and cell
type were all independent determinants of survival. Differences in survival from the various prognostic groups
were impressive with 5-year survival rates ranging from 7 to 62%. However, these differences were not
qualitative (i.e. the kinetics of survival were similar for the best and the worst groups) suggesting that current
prognostic factors are of little use for selecting 'biologically' different sub-populations. Platinum-based
regimens were associated to an overall prolonged median survival, but this benefit was not observable in the
subgroup with most favourable prognosis (<2 cm residual tumour size). The implications of these observa-
tions for clinical research and ovarian cancer patients care are discussed.
Cancer of the ovary ranks sixth as a fatal form of cancer in
women and is the second cause of death for gynaecological
malignancies in Italy. Approximately 4,000 women die of it
every year in Italy (Cislaghi et al., 1986).
In the mid 1970s surgery and radiotherapy played major
roles in the management of this disease while chemotherapy,
although extensively explored, was still considered experi-
mental. Survival rates at 5 years were below 10% in the
advanced stages, representing more than 70% of patients at
diagnosis.
Among the clinical research goals set forth at that time
was the determination of prognostic factors. As for other
tumours, prognostic determinants were sought to understand
the natural history of the disease, to adjust for randomisation
imbalances in the interpretation of clinical trials results and
to provide clinicians with guidelines for decisions on treat-
ment strategies and for dealing with the patients and their
relatives. Earlier studies were generally based on univariate
analyses (Richardson et al., 1985), and their conclusions are
marred by all the pitfalls associated with a statistical method
not accounting for interactions between different variables.
Griffiths (1975) was the first to use multiple regression and
multivariate analysis of possible prognostic factors, but
his database was small (102 cases) and comprised also stage
II patients. Recently several studies (Swenerton et al., 1985;
Redman et al., 1986; Gruppo Interregionale Cooperativo
Oncologico Ginecologia, 1987; Neijt et al., 1984, 1987;
GGCOSA, 1986) using multivariate analysis have demon-
strated that response and survival in this disease are vastly
influenced by a variety of interrelated disease and patient-
related factors. The role of these factors needs to be further
investigated, both because of the complexity of their relation-
ship with treatment outcome and because of the small sample
size of many trials in which these factors were originally
studied.
In the past 10 years our group (GICOG) has treated
almost a thousand patients with advanced epithelial ovarian
cancer, accrued in four consecutive randomised clinical trials.
The main purpose of this paper is to identify those factors,
including treatment, that can predict survival, in a large
patient population followed, over the years, by the same
group of surgeons and medical oncologists.
Subjects and methods
Patients
From 1978 to 1986, 914 patients with epithelial ovarian
cancer, FIGO stage III and IV, were referred to any of the
nine GICOG clinics and treated according to one of the
protocols shown in Table I. One investigator (C. Mangioni;
Monza) accrued 34% of the entire population.
Requirements for eligibility included: (1) histologically
proven epithelial cancer of the ovary, (2) absence of prior
chemotherapy and/or radiotherapy, (3) absence of life-
threatening organ dysfunctions and careful staging according
to FIGO indications and on the operative report of the
surgeon. All randomisations were stratified by residual
tumour size (<2cm/>!2cm) and by centre.
All patients underwent surgical exploration through a
xypho-pubic incision. All possible tumour was removed.
When indicated, total abdominal hysterectomy (TAH), bi-
lateral salpingoophorectomy (BSO) and infracolic omentec-
tomy (0) were performed. Suspect lymph nodes, and liver or
diaphragmatic abnormalities were biopsied. In patients with
optimal stage III random biopsies were also taken.
Treatment schedules and drug dosages and modulations
have been described in detail elsewhere (Gruppo Interregion-
ale Cooperativo Oncologico Ginecologia, 1987; Bolis et al.,
1980; Sessa et al., 1985; Mangioni et al., 1989). Table I gives
a synopsis of treatments in the four trials.
Table II shows the characteristics of the patient population
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Table I Treatments protocols for four trial
Trial Drug(s) Schedule
Cyclophosphamide 100mg day', p.o. continuously
1975-78 vs
AC/C cyclophosphamide 100mgday', p.o. continuously
doxorubicin 50mgm-2 i.v., q 28 days up to 450mgm-2
2 Cyclophosphamide 70mgm 2 daily 1 -141
1978-80 doxorubicin 50mgm- i.v q 28 days
HAC/PAC cisplatin 50mg m-2 i.v.
vs
cyclophosphamide 70mgm-2 daily 1-141
doxorubicin 50mg m-2 i.v. q 28 days
hexamethylmelamine 150mg m-2 p.o. days 1-14
3 Cyclophosphamide 650mg m-2 i.v.
1980-86 doxorubicin 50mgm2 i.v. q 28 days
PAC/CP/P cisplatin 50mg m-2 i.v.
vs
cyclophosphamide 650mgm-2 i.v. q 28 days
cisplatin 50mg m-2 i.v.
vs
cisplatin 50mgm-2 i.v. q 28 days
4b Cisplatin 100mg m-2 i.v. q 28 days
1984-87 vs
CBDCA/PlOO carboplatin 400mg m-2 i.v. q 28 days
uCyclophosphamide was administered i.v. on day I and p.o. on days 2-14. 'Trial 4 was started in 3/9
GICOG institutions, while trial 3 was still open for the remaining institutions.
Table 11 Patients' characteristics according to trial
1 2 3 4
n=53 n= 107 n=529 n= 163
Characteristics No. (%) No. (%) No. (%) No. (%)
Age
< 50 24 (45.3) 42 (39.2) 156 (29.5) 40 (24.5)
> 50 29 (54.7) 65 (60.8) 373 (70.5) 123 (75.5)
PS score (median) 90 90 90 90
FIGO stage
III 48 (90.6) 97 (90.7) 429 (81.1) 192 (77.3)
IV 5 ( 9.4) 10 ( 9.3) 100 (18.9) 37 (22.7)
Size ofresidual tumour
<2cm 16 (30.2) 31 (29.0) 163 (30.8) 36 (21.2)
2-5 cm 10 (18.9) 21 (19.6) 104 (19.7) 37 (22.7)
> 5 cm 27 (50.9) 55 (51.4) 262 (49.5) 90 (55.2)
Histotype
Serous 48 (90.6) 70 (65.4) 326 (61.6) 98 (60.1)
Endometrioid 3 ( 5.7) 8 ( 7.5) 64 (12.2) 19 (11.7)
Clear cell 0 16 (1.5) 19 ( 3.6) 9 ( 5.5)
Mixed 2 (3.8) 4 (3.7) 28 (5.3) 11 ( 6.7)
Mucinous 0 8 ( 7.5) 71 (13.4) 19 (11.7)
Undifferentiated 0 1 (0.9) 21 ( 4.0) 7 (4.3)
FIGO grade
I 0 19 (17.8) 75 (14.2) 12 ( 7.4)
2 5 ( 9.4) 31 (29.0) 185 (35.0) 53 (32.5)
3 48 (90.6) 57 (53.3) 269 (50.8) 98 (60.1)
Abdominal cytology
Positive 30 (56.6) 69 (64.5) 399 (75.5) 85 (52.2)
Negative 15 (28.3) 7 ( 6.5) 42 ( 7.9) 32 (19.6)
Not evaluated 8 (15.1) 31 (29.0) 88 (16.6) 46 (28.2)
Type ofsurgery
Exlorative LPT 20 (37.7) 29 (27.1) 70 (13.2) 22 (13.5)
BSO±TAH 19 (35.8) 47 (43.9) 200 (37.8) 35 (21.5)
TAH + BSO + O±Ly 14 (26.4) 31 (29.0) 259 (49.0) 106 (65.0)
LPT, laparotomy; 0, omentectomy; Ly, lymphadenectomy; TAH, total abdominal
hysterectomy; BSO, bilateral salpingoophorectomy.
by trial. Out of the 914 patients, 62 (6.8%) have been ex-
cluded from every analysis, and are not reported in Table II,
for one or more of the following reasons: borderline tumour
(n = 4), unknown FIGO grade (n = 40), age (n = 1), histotype
(n = 5) and residual tumour size (n = 16). For the remaining
852 patients information was available on the following vari-
ables: residual tumour after first surgery, histotype, FIGO
stage and grade, age, type of response, center of treatment
and type of surgical treatment. Information on performance
status (PS) and abdominal cytology was unavailable for
respectively 131 and 173 patients. Of the 721 patients for
whom information on PS was available, 152 lacked data on
abdominal cytology. As described elsewhere (Gruppo Inter-
regionale Cooperativo Oncologico Ginecologia, 1987; Bolis et
al., 1980; Sessa et al., 1985; Mangioni et al., 1989), all known
prognostic indicators were balanced between treatment
groups within each separate trial.446 S. MARSONI et al.
Evaluation and statistical methods
Survival is the only end-point considered in this analysis.
Death as the only measure of outcome was chosen because
this event is unaffected by those time-related biases which
may alter end-points such as response or progression-free
survival and are almost unavoidable in a retrospective
analysis. Time on study or time to death were calculated
from the day offirst surgery to the cut-off date or to death, if
this occurred. Kaplan & Meier (1958) and log-rank test
(Tarone & Ware, 1977) methods were used respectively to
estimate and compare survival curves (the expected number
of events are calculated in the log-rank test under the null-
hypothesis).
The Cox model (Cox, 1972) was used for multivariate
analysis on survival. Graphic checks of the proportionality
assumption were made in all analyses. A significance level of
5% was adopted in all the two-tailed tests.
Prognostic factors taken into account in the step-wise Cox
analysis on survival were residual tumour size (<2, 2-5,
>5 cm) FIGO stage (III, IV) and grade; cell type (serous,
endometrioid + clear cell + mixed, mucinous, undifferen-
tiated, age, centre (Monza, Brescia, others)); type of first
surgery (explorative laparotomy, TAH + BSO ± 0± lymph-
adenectomy, BSO ± 0± lymphadenectomy). Two further
sets of analyses were done on the subset of patients for
whom information on performance status (PS, Karnofsky
index 100-90, <90, n = 721) and abdominal cytology
(positive, negative, n = 568) was also available. The variable
treatment was used as a correction factor in Cox regression
analysis.
Cut-off date for the analysis was 31 December 1988; the
median and the longest follow-up times are respectively 56
and 122 months. There are 31% of patients withdrawn alive
(66% in trial 4 and 23% in trials 1-3).
Results
Table III shows the final results of Cox analysis on the whole
population (852 patients) and does not include FIGO grade,
centre, and type of surgery because these did not significantly
affect the probability of surviving. Age >50 years, stage IV
disease, cell type other than serous and tumour size more
than 5 cm were associated with a higher probability of death.
The risk of dying rose progressively with the size of residual
tumours from 1 in the <2 cm category, two-fold for 2-5
cm, and three-fold in the >5 subgroup.
The same analysis was repeated on the subset of 721
patients for whom PS were available (Table III). By adding
this variable, tumour size and cell type remained important
determinants but the other previously significant factors -
stage and age - lost their prognostic value. A good PS
(100-90) carried significant benefit. The same anlaysis was
repeated in a further reduced subset of 568 cases for whom
information was available on abdominal cytology. This vari-
able did not significantly affect survival or change the
previous results.
Each subgroup by residual tumour size (<2 cm, 2-5,
> 5 cm) was further divided according to the remaining
prognostic variables identified by Cox analysis - performed
Table III Final results of Cox's regression analysisa
All cases Cases with PS
Regression variables (n = 852) (n = 721)
Age (years)
<50
, 50
FIGO stage
III
IV
Cell type
Serous
Others
Residual tumour
<2cm
2-Scm
>5cm
Performance status (PS):
90- 100
>90
1.4 (1.2-1.6)
2.12 (1.6-2.7)
3.15 (2.8-4.4)
n.s.
n.s.
1.4 (1.2-1.7)
2.3 (1.7-3.0)
3.2 (2.5-4.0)
1.5 (1.2-1.8)
aRelative risk (95% Cl). bReference level assigned a value of1.0. The
higher the risk, the greater the probability ofdying; the lower the risk
(i.e. < 1), thehigher theprobability ofsurviving. n.s. = notsignificant.
on the whole population (n = 852) - to be significant (cell
type) or borderline significant (age, stage). Six prognostic
groups were thus created. In each subgroup, patients featur-
ing the best combination of prognostic characteristics (age
< 50 years, serous cell type and stage III) were juxtaposed to
patients presenting all other combinations.
Table IV sets out the distribution of patients by prognostic
class and the relative observed/expected (O/E) ratios, 5-year
survival and median survival times (MST). In patients with
residual tumour <2 cm, the additional co-factors different-
iated between two distinct populations with 5-year survival
rates 62% and 41% and median survival times of 108 and 36
months. In the other two sub-groups, 2-5 cm and >5 cm,
younger age, lesser stage and presence of serous cell type do
not seen to have a relevant impact on the prognostic strength
of the tumour size.
Figure la and b shows the overall survival curve and the
curves for the entire population stratified according to the six
prognostic classes.
Figure 2a gives the curves by residual tumour size alone
and Figure 2b the curves for the <2 cm population further
broken down (microscopic, <1 cm, 1-2 cm). The popula-
tion with microscopic disease was equally distributed between
the two first sub-groups of risk categories (<2 cm, good risk
and <2 cm, poor risk).
Table V also sets out the distribution of patients by prog-
nostic class, but utilises the class definition derived from Cox
analysis performed on the subset of 721 patients for whom
PS was available. The risk classes thus identified are less
distinctively differentiated in terms of 5 years survival and
median survival time, when compared with those obtained
through the first analysis.
Table VI sets out the O/E ratios overall and after strati-
fication by tumour size (<2 cm, 2-5, > 5 cm), by trial and
by treatment. Three observations can be made when con-
sidering the overall O/E ratios: (1) the first trial, comparing
Table IV Prognostic groups according to Cox analysis
Prognosticfactors Patients
RTiS Age OIE' % Syears MSTc
Group (cm) Stage (years) Cell type No. % ratio survival (months)
1 <2 III <50 serous 62 7 0.32 62 108
2 <2 any any any 184 22 0.56 41 36
3 2-5 III <50 serous 32 4 0.97 21 24
4 2-5 any any any 140 16 0.96 22 20
5 >5 III <50 serous 45 5 1.18 14 18
6 > 5 any any any 389 46 1.64 7 15
'Residual tumour size; bobserved/expected; cmedian survival time.
I
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Figure 1 a, Overall survival. b, Survival by risk-group (see Table
IV for risk group definition). 0 group 1, A group 2, group 3,
0 group 4, 0 group 5, A group 6.
single agent cyclophosphamide and the combinations with
adriamycin (AC) shows the highest O/E ratio; (2) the addi-
tion of a third active drug to the AC combination (i.e.
cisplatin or hexamethylmelamine) reduced the O/E to the
unity; and (3) the latest trial comparing single agent high-
dose (100 mg) cisplatin to carboplatin shows the lowest O/E
ratio. The same pattern was evident after stratification by
residual tumour size.
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Figure 2 a, Survival by residual tumour size after first surgery:
0 <2 cm, A 2-5 cm, >5 cm. b, Survival by residual tumour
size after first surgery: * absent or microscopic, A <1 cm,
> 1 cm.
When the O/E ratios within each separate trial are con-
sidered, the pattern is the same as for the overall O/E, with
no major differences between treatment arms, although in
trial no. 3 low-dose (50 mg m2) cisplatin alone arm (CAP vs
CP vs P) had an O/E of 1.20 compared to ratios below unity
for the two combination arms (CAP and CP).
Figure 3 is the graphic correspondent of Table VI, showing
the survival curves for each trial. The AC/C trial is doing
significantly worse, the high-dose cisplatin/carboplatin arm
shows better survival, although with a much shorter follow-
up, while the curves for HAC/PAC and CAP/CP/P trials are
superimposed and in an intermediate position. Survival
curves stratified by residual tumour size are shown in Figure
4a (<2 cm), b (2-S cm) and c (> 5 cm). In the subgroup of
246 patients with residual tumour size below 2 cm the sur-
vival curves for the four trials are completely superimposed
and the worse survival experience observed for the whole
population in trial no. 1 (C vs AC) is no longer detectable
Table V Prognostic factors according to Cox analysis including performance status
(PS)
Prognosticfactors Patients
RT.S OIE" % 5 years MSTC
Group (cm) PS Cell type No. % ratio survival (months)
1 <2 >90 serous 101 14 0.40 50 43
2 <2 any any 104 14 0.58 36 32
3 2-5 >90 serous 71 10 0.75 28 21
4 2-5 any any 70 10 1.41 17 7
5 >5 >90 serous 151 21 1.22 19 7
6 > 5 any any 224 31 1.75 14 5
'Residual tumour size; bobserved/expected; cmedian survival time.
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Figure 3 Survival by trial: * trial 1-AC/C, A trial 2 HAC/
PAC, U trial 3 PAC/CP/P, 0 trial 4 carboplatin/P 100.
Table VI Observed/expected ratio by trial and treatment
Trial No. of No. of
no. OIE ratio Arms OIE ratio pts events/trial
C 1.47 (1.88)
1 1.54 (1.91) 63 47
AC 1.67 (1.95)
HAC 1.05 (1.03)
2 0.95 (0.94) 107 84
PAC 0.89 (0.94)
CAP 0.89 (0.86)
3 1.02 (1.03) CP 0.98 (0.94) 529 399
P 1.20 (1.23)
P100 0.61 (0.54)
4 0.73 (0.66) 163 55
JM8 0.88 (0.81)
In parenthesis is the O/E after stratification by residual tumour size
(<2 cm, 2-5, > 5cm).
(Figure 4a). However, the pattern of a marked difference
between trial 1 and all the others, and with the caveat of the
shorter follow-up, the superiority of trial 4, reappears when
plotting the survival curves for the >2 cm sub-groups
(Figure 4b, 2-5 cm; Figure 4c, >5 cm).
Discussion
The aim of this paper was a critical analysis of the results
from four randomised clinical trials, inclusive of more than
850 patients, conducted by a single cooperative group in
advanced epithelial ovarian cancer in the last decade. There
were several purposes for the analysis: (1) to determine
the impact of selected prognostic variables on survival of
advanced ovarian cancer patients; (2) to obtain, from the
interaction of favourable prognostic factors and treatment,
an approximative estimate of the magnitude of the survival
advantage associated with the use of platinum-based com-
bination chemotherapy; and (3) to establish the implications
of these two points for clinical research and ovarian cancer
patients care.
Impact ofselectedprognostic variables on survival ofadvanced
ovarian cancer patients
Residual tumour size is the major determinant of survival. As
defined by the multivariate analysis, the addition of age,
stage and histology further identify a sub-population within
the less than 2 cm subgroup, with a better prognosis (Table
IV). However, this subgroup comprises less than 10% of the
overall population and its survival curve does not seem to
have reached a plateau even after 5 years. For patients with
residual tumour in excess of 2 cm addition of the other
prognostic variables fails to discriminate among subgroups
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Figure 4 a, Survival by trial in patient with residual tumour size
after first surgery <2 cm: 0 trial I AC/C, A trial 2 HAC/PAC,
* trial 3 PAC/CP/P, 0 trial 4 carboplatin/P. b, Survival by trial
in patients with residual tumour size after first surgery 2-5cm:
* trial 1 AC/C, A trial 2 HAC/PAC, U trial 3 PAC/CP/P, 0
trial 4 carboplatin/P. c, Survival by trial in patients with residual
tumour size after first surgery >5S cm: 0 trial I AC/C, A trial 2
HAC/PAC, U trial 3 PAC/CP/P, 0 trial 4 carboplatin/P.
with markedly different survival experience (Figure lb).
PS was another strong independent factor affecting survi-
val. The addition of this variable in the Cox model yielded a
1.5 relative risk of dying for patients with a PS score below
90, while nullifying the influence of stage and age. This is not
surprising since PS could be a 'comprehensive' marker of the
same relationship between the patient's status and the extent
of disease expressed by the combination of stage and age in
the first model, despite the different nuances.
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on the importance of residual tumour as a prognostic deter-
minant, the prognostic importance of all other variables
varied from one study to another (Griffiths, 1975; Swenerton
et al., 1985; Redman et al., 1986; Gruppo Interregionale
Cooperativo Oncologico Ginecologia, 1987; Neijt et al., 1984,
1987). This may be accounted for by both the small popula-
tions studied (in all cases fewer than 200 patients were
analysed) and the different 'cocktails' of factors considered
(several included weight loss, other excluded age and/or
stage, etc). The strength of this study is the large sample on
which results are based. However, the relevance of prognostic
factors other then residual tumour size should be further
tested to avoid biases inherent to retrospective and subgroup
analysis. The results presented in Table IV and Figure lb
need to be prospectively validated on an independent data
set.
Approximate magnitude ofthe survival advantage associated
with platinum-based combination chemotherapy in ovarian
cancer
The overall 5-year survival rate in advanced epithelial cancer
in this series of 852 patients treated between 1978 and 1987 is
twice that reported historically (Richardson et al., 1985) for
5,254 cases collected from 1973 to 1974 (22.1, 95% CL
18.7-25.4 vs 10.4%). In addition the 1, 2 and 3 year survival
figures are practically the same as in the most recent trials
utilising aggressive polychemotherapies like the CHAP-5 regi-
men (Neijt et al., 1984, 1987).
Since we pooled data from four consecutive trials, in the
multivariate analysis we considered type of treatment only as
a correcting factor for determining the influence of the
various prognostic variables on survival. However, survival
was also influenced by treatment or at least by type of
strategy, as can be seen from Figure 3 and Table VI. This
observation must be tempered in consideration of the histori-
cal nature of our analysis which can be biased by changes in
the characteristics of the treated groups and in the types of
ancillary treatment and/or diagnostic work-up (Table II sug-
gests a worsening of the patients over time, in spite of a
higher incidence of more aggressive surgery). That not with-
standing, patients treated with the earlier strategic approach,
single agent cyclophosphamide or a combination of cyc-
lophosphamide and adriamycin did worse than all the others.
Patients exposed to cisplatin - either alone at high-doses
(100 mg m2) or in combination (CP, CAP) at low-doses
(50 mgm2) - did better, but the HAC treated patients did no
worse than the previous category. However, if platinum-
based chemotherapies - either single agent or combinations -
seem to have prolonged the median survival time in advanced
ovarian cancer patients, the fraction of long-term survivors
has not increased markedly, especially in the sub-group most
susceptible of being cured (i.e. patients with less than 2 cm
residual tumour, Figure 3a). In fact, results from randomised
trials, our own (Gruppo Interregionale Cooperativo Onco-
logico Ginecologia, 1987) and more recent ones (Neijt et al.,
1987; Omura et al., 1983; Tomirotti et al., 1988), suggest that
if a difference exist between less aggressive regimens (cis-
platin, cisplatin + cytoxan) and CAP is of an order of mag-
nitude much lower than that hoped for in the early 1980s (i.e.
less than 20%).
Implicationsfor clinical research and care in ovarian cancer
Prognostic factors are sought not only to help understand the
natural history of a disease but also for more 'decisional'
purposes in both clinical practice and research.
In clinical practice, the knowledge that advanced ovarian
cancer patients can be assigned to groups with distinct prog-
nostic characteristics may serve doctors as a guideline for a
more accurate estimate of the trade-offs between toxicity and
survival offered by chemotherapy.
In clinical research, prognostic factors are often used for
adjusting for randomisation imbalances in the analysis/inter-
pretation of clinical trial results. This work suggests there
is great heterogeneity - in terms of survival probabilities -
within an apparently homogeneous population, historically
labelled as 'advanced disease'. The difference in survival
between the best-prognosis group and all the others is im-
pressive. It follows that the results of any trial could quite
dramatically change - and independently from the real
impact of whatever experimental treatment was tested -
depending on the size of this fraction of patients. Since
generally not more than 20% of the patient population for a
given tumour type, including ovarian, seen at any given
institution (Wittes & Friesman, 1988), enters controlled
clinical trials, this kind of selection bias could conceivably
play a role in up-grading (or down-grading) the final results
of the trial itself.
This might partially explain the different results obtained
by different centres/investigators utilising similar regimens in
advanced ovarian cancer (Tomirotti et al., 1988; Neijt et al.,
1987; Decker et al., 1982; Bell et al., 1982; Conte et al., 1986;
Williams et al., 1985; Young et al., 1978; Bertelsen et al.,
1987; Wilbur et al., 1987; Carmo-Pereira et al., 1983; Omura
et al., 1986). It also strikes a point against historical com-
parisons in which the lack of randomisation is even more
likely to unbalance the prognostic subgroups and conse-
quently introduce powerful biases in the conclusions.
To facilitate international communication of data, com-
mon criteria for defining and reporting risk groups in this
disease should perhaps be developed and agreed upon, as has
been done for other diseases (Mastrangelo et al., 1986).
The second implication for clinical research stems from the
recognition that the differences in survival among the various
prognostic groups, although impressive, are quantitative, not
qualitative. In other world the 'kinetics' of survival of the
best and worst risk groups are similar. Thus the current
prognostic factors are useless for selecting a 'biologically'
different sub-population, as was done, for example, within
the acute leukaemias for the B immunophenotype. The cur-
rent prognostic factors in ovarian cancer probably represent
a too remote epiphenomenon(a) of the underlying abnormal-
ity(ies) to be of use for this purpose.
Finally, no striking differences were observed in the long-
term results with eight different mono or polychemotherapy
regimens. The results of other randomised clinical trials
in the past decade point in the same direction (Gruppo
Interregionale Cooperativo Oncologico Ginecologia, 1987;
GGCOSA, 1986; Bell et al., 1982; Williams et al., 1985;
Dembo, 1986; Burslem & Wilkinson, 1986). They suggest a
superiority in terms of response and progression-free disease
of combination chemotherapy over single-agent alkylators or
cisplatin, but are ambiguous in terms of survival and cost/
benefit ratios possibly because much larger sample sizes are
needed to detect small survival differences (i.e. 10% or less).
The implications are two-fold: first that clinical research in
this disease has reached a plateau phase, and secondly that
efforts should be directed beyond the repetitive area of com-
paring 'new' combinations of old drugs. Perhaps while await-
ing new drugs or truly innovative new ideas, clinical research
in this area should tackle the fact that although cisplatin-
based chemotherapy seems to play an important role, we are
far from having established any universally acceptable stan-
dard.
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for fruitful discussion. The generous contribution of the Italian
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